logo
Share SHARE
FONT-SIZE Plus   Neg

SINA Profit Tops Estimates, Stock Rises - Update

SINA Corp. (SINA), a provider of online media and mobile value-added services in China, on Tuesday reported lower profit for the fourth quarter, amid a modest rise in revenue. Adjusted earnings topped Wall Street estimates. The stock surged in the extended session.

Net income attributable to SINA for the quarter plunged to $2.4 million or $0.03 per share from $9.3 million or $0.14 per share for the same period last year.

Adjusted earnings totaled $0.13 per share, while it amounted to $0.21 per share in the previous year. On average, 11 analysts polled by Thomson Reuters expected earnings of $0.05 per share for the quarter. Analysts' estimates typically exclude special items.

Net revenues for the quarter rose 4 percent to $139.13 million from $133.4 million. Non-GAAP net revenues for the fourth quarter of 2012 totaled $134.4 million, up from last year's $128.7 million. Analysts had a consensus revenue estimate of $133.86 million for the quarter.

Advertising revenues grew 7 percent to $110.7 million from $103.7 million. Non-advertising revenues slipped 4 percent to $28.5 million.

Gross margin for the fourth quarter was 57 percent, compared to 54 percent for the same period last year. Operating expenses climbed to $73.8 million from $66.7 million.

The company estimates that its non-GAAP net revenues for the first quarter of 2013 will be between $115 million and $119 million. This excludes the recognition of $4.7 million in deferred license revenues related to SINA's equity investment in E-House/CRIC. Analysts have consensus revenue estimate of $117.39 million for the first-quarter.

SINA closed at $53.48 on Tuesday, down 4.5 percent from the previous close, but added 6.4 percent in the extended session.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The month of February saw the FDA approve the second drug for Duchenne muscular dystrophy namely Emflaza. Now, let's take a look at the biotech stocks awaiting FDA decision in March. The recent week marked the lull before the storm, with very few market moving economic numbers released during the week. However, the economic news flow picks up pace in the upcoming week, offering glimpses into every vehicle of economic growth, ranging from consumers to private sector activity to housing.... Life expectancy at birth in the U.S. is already lower than most other developed nations and is now projected to fall further behind by 2030, according to a new study. It also suggests that by 2030, national female life expectancy in South Korea could break the 90 year barrier.
comments powered by Disqus
Follow RTT